Physician profile
Deborah E Levenson
NPI 1952406688
$202.66
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.32 | 2019 | |
| Pfizer INC. | $32.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.27 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.44 | 2019 | |
| Allergan, INC. | $15.04 | 2019 | |
| Shionogi INC | $14.73 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Levenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.